Assessment of Atherosclerotic risk among United Arab Emirates Population: A Cross-Sectional Study
Main Article Content
Keywords
Atherosclerotic, cardiovascular disease risk, associated variables, sociodemographic characteristics
Abstract
Background: Cardiovascular disease (CVD) continues to be a major health concern associated with a high mortality rate. Assessing atherosclerotic risk is a crucial role in preventing future cardiovascular disorders and halting disease progression. Patients at risk of cardiovascular development are recommended to implement lifestyle modifications and initiate appropriate pharmacologic therapies. Objectives: The objectives are to assess the atherosclerotic cardiovascular disease risk (ASCVD) and evaluate the effect of the sociodemographic characteristics. Methodology: This was a cross-sectional study conducted between April and September 2023 through an online questionnaire distributed in hospital and community pharmacies via social media platforms. Results: A total of 440 participants were enrolled in the study, majority 85.5% were males within the age range of 40 to 59 years. Over a third of the participants (37.5%) were classified as having a low risk of developing atherosclerotic cardiovascular disease (ASCVD). In contrast, only 11.4% of the participants were found to have a high risk of developing ASCVD. An increase in the odds of ASCVD high risk category was significantly associated with increased age, income, being a smoker, and increased distress with a p-value <0.05. Conversely, being a female, working in the medical field, and receiving no Aspirin were significantly associated with lower odds of high risk ASCVD category with a p-value <0.05. Conclusion: Our study concluded that the majority of the participants had moderate to high ASCVD risk and the risk is higher with advanced age, smoking status, and increased distress level. Our study highlights the importance of initiating early medications and increasing awareness among patients.
References
2. Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Krist AH, Kubik M. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. Jama. 2022 Apr 26;327(16):1577-84. https://doi.org/10.1001/jama.2022.4983
3. Duber HC, McNellan CR, Wollum A, Phillips B, Allen K, Brown JC, Bryant M, Guptam RB, Li Y, Majumdar P, Roth GA. Public knowledge of cardiovascular disease and response to acute cardiac events in three cities in China and India. Heart. 2018 Jan 1;104(1):67-72. https://doi.org/10.1136/heartjnl-2017-311388
4. Gaidai O, Cao Y, Loginov S. Global cardiovascular diseases death rate prediction. Current Problems in Cardiology. 2023 Jan 29:101622. https://doi.org/10.1016/j.cpcardiol.2023.101622
5. Fidalgo P, Thormann J, Kulyk O, Lencastre JA. Students’ perceptions on distance education: A multinational study. International journal of educational Technology in Higher Education. 2020 Dec;17(1):1-8. https://doi.org/10.1186/s41239-020-00194-2
6. Hall HM, de Lemos JA, Enriquez JR, McGuire DK, Peng SA, Alexander KP, Roe MT, Desai N, Wiviott SD, Das SR. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circulation: Cardiovascular Quality and Outcomes. 2014 Sep;7(5):701-7. https://doi.org/10.1161/CIRCOUTCOMES.113.000822
7. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, Crenshaw DL, Effron MB, Re RN, Gupta K, Anderson RD. Comparative effectiveness of aspirin dosing in cardiovascular disease. New England Journal of Medicine. 2021 May 27;384(21):1981-90. https://doi.org/10.1056/NEJMoa2102137
8. Kazim MN, AbouMoussa TH, Al-Hammadi FA, Al Ali A, Abedini FM, Ahmad FS, Bazdar MY, Carrick FR, Abdulrahman M. Population awareness of cardiovascular disease risk factors and health care seeking behavior in the UAE. American Journal of Preventive Cardiology. 2021 Dec 1; 8:100255. https://doi.org/10.1016/j.ajpc.2021.100255
9. Krauss E, Cronin M, Dengler N, Segal A. Interaction between low-dose aspirin and nonsteroidal anti-inflammatory drugs can compromise aspirin’s efficacy in preventing venous thrombosis following total joint arthroplasty. Clinical and Applied Thrombosis/Hemostasis. 2020 May 14; 26:1076029620920373. https://doi.org/10.1177/1076029620920373
10. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB. Effect of aspirin on disability-free survival in the healthy elderly. New England Journal of Medicine. 2018 Oct 18;379(16):1499-508. https://doi.org/10.1056/NEJMoa1800722
11. Mezhal F, Oulhaj A, Abdulle A, AlJunaibi A, Alnaeemi A, Ahmad A, Leinberger-Jabari A, Al Dhaheri AS, AlZaabi E, Al-Maskari F,
Alanouti F. High prevalence of cardiometabolic risk factors amongst young adults in the United Arab Emirates: the UAE Healthy Future Study. BMC Cardiovascular Disorders. 2023 Mar 15;23(1):137. https://doi.org/10.1186/s12872-023-03165-3
12. Mujamammi AH, Alluhaymid YM, Alshibani MG, Alotaibi FY, Alzahrani KM, Alotaibi AB, Almasabi AA, Sabi EM. Awareness of cardiovascular disease associated risk factors among Saudis in Riyadh City. Journal of family medicine and primary care. 2020 Jun;9(6):3100. https://doi.org/10.4103/jfmpc.jfmpc_458_20
13. Mukattash TL, Shara M, Jarab AS, Al-Azzam SI, Almaaytah A, Al Hamarneh YN. Public knowledge and awareness of cardiovascular disease and its risk factors: a cross-sectional study of 1000 Jordanians. International Journal of Pharmacy Practice. 2012 Dec;20(6):367-76. https://doi.org/10.1111/j.2042-7174.2012.00208.x
14. Nansseu JR, Noubiap JJ. Aspirin for primary prevention of cardiovascular disease. Thrombosis Journal. 2015 Dec;13(1):1-0. 10.29328/journal.jccm.1001172
15. AlQuaiz AM, Kazi A, Alodhayani AA, Almeneessier A, AlHabeeb KM, Siddiqui AR. Age, and gender differences in the prevalenceof chronic diseases and atherosclerotic cardiovascular disease risk scores in adults in Riyadh city, Saudi Arabia. Saudi Medical Journal. 2021 May;42(5):526. https://doi.org/10.15537/smj.2021.42.5.20200684
16. Al-Rifai M, et al. Awareness, Attitudes, and Beliefs About Aspirin Use for Primary Prevention of Cardiovascular Disease Among Older US Adults. Journal of the American Heart Association. 2020;9(3): e014221. https://doi.org/10.1161/JAHA.119.014221
17. Kazim MN, AbouMoussa TH, Al-Hammadi FA, Al Ali A, Abedini FM, Ahmad FS, Bazdar MY, Carrick FR, Abdulrahman M. Population awareness of cardiovascular disease risk factors and health care seeking behavior in the UAE. American Journal of Preventive Cardiology. 2021 Dec 1; 8:100255. https://doi.org/10.1016/j.ajpc.2021.100255
18. Gluckman TJ, Kovacs RJ, Stone NJ, Damalas D, Mullen JB, Oetgen WJ. The ASCVD risk estimator app: from concept to the current state. Journal of the American College of Cardiology. 2016 Jan 26;67(3):350-2. https://doi.org/10.1016/j.jacc.2015.10.068
19. Kawada T. Socioeconomic status and cardiovascular disease. International Journal of Cardiology. 2019 Jan 1; 274:378. https:// doi.org/10.1016/j.ijcard.2018.07.034
20. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F. Metabolic health in the Middle East and north Africa. The lancet Diabetes & endocrinology. 2019 Nov 1;7(11):866-79. https://doi.org/10.1016/S2213-8587(19)30179-2
21. Georgoulis M, Chrysohoou C, Georgousopoulou E, Damigou E, Skoumas I, Pitsavos C, Panagiotakos D. Long-term prognostic value of LDL-C, HDL-C, lp (a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002–2012). Lipids in Health and Disease. 2022 Dec 19;21(1):141. https://doi.org/10.1186/s12944-022-01747-2
22. Goldsborough E, Osuji N, Blaha MJ. Assessment of cardiovascular disease risk: a 2022 update. Endocrinology and Metabolism Clinics. 2022 Sep 1;51(3):483-509. https://doi.org/10.1016/j.ecl.2022.02.005
23. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11): e596-646. https://doi.org/10.1161/CIR.0000000000000678
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.